BrainsWay Ltd. (BWAY)

Market Cap	243.13M
Revenue (ttm)	43.46M
Net Income (ttm)	3.92M
Shares Out	36.90M
EPS (ttm)	0.08
PE Ratio	62.07
Forward PE	44.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,977
Open	12.30
Previous Close	12.64
Day's Range	12.16 - 12.37
52-Week Range	5.98 - 13.66
Beta	0.25
Analysts	Strong Buy
Price Target	14.25 (+15.29%)
Earnings Date	Aug 5, 2025

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Analyst Summary

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 15.29% from the latest price.

Price Target

$14.25

(15.29% upside)

Analyst Consensus: Strong Buy